Meeting
2013 ASCO Annual Meeting
A phase II study of radiation therapy (RT), paclitaxel poliglumex (PPX), and cetuximab (C) in locally advanced head and neck cancer (LA-HNC).
Authors
Seung Shin Hahn
SUNY Upstate Medical University, Syracuse, NY
Seung Shin Hahn , Jeffrey Bogart , Chung Taik Chung , Jack Hsu , Robert Kellman , Michael Andrew Lacombe , Jung-AH Kim , Stephen L. Graziano , Dena Martin , Ajeet Gajra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT00660218
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6059)
DOI
10.1200/jco.2013.31.15_suppl.6059
Abstract #
6059
Poster Bd #
12G
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.
First Author: Thiago Bueno Oliveira Sr.
Poster
2021 ASCO Annual Meeting
Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
First Author: Christophe Le Tourneau
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
First Author: Felix Keil
Poster
2018 ASCO Annual Meeting
A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.
First Author: Xu Shan Sun